Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 159 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infliximab (Remicade) Clear all
Not listed No phase listed Observational

Registry for Advanced Sarcodiosis

NCT03769987
View directory record Official record
Conditions
Sarcoidosis
Interventions
observation
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
15 Years to 100 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Sep 30, 2026, 7:23 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.

NCT03269695
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PF-06687234, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
14
States / cities
Dothan, Alabama • Atlanta, Georgia • Chevy Chase, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 4 Interventional Results available

Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery

NCT00688636
View directory record Official record
Conditions
Crohn's Disease
Interventions
infliximab, placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 72 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Sep 30, 2026, 7:23 PM EDT
Completed No phase listed Observational

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints

NCT04798287
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tofacitinib, TNF Inhibitor
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
105,711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 4 Interventional Results available

Safety of Reduced Infliximab Infusion Time

NCT05340764
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Infliximab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Sep 30, 2026, 7:23 PM EDT
Active, not recruiting No phase listed Observational

Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis

NCT03765450
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Infliximab
Drug
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Active, not recruiting No phase listed Observational

A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants

NCT06126835
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ozanimod, Conventional therapy, Advanced therapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
2,828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 30, 2026, 7:23 PM EDT
Recruiting No phase listed Observational

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

NCT07237516
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn's Disease (CD), Indeterminate Colitis, Inflammatory Bowel Disease (IBD)
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
New Haven, Connecticut • Miami, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Not listed No phase listed Observational

Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

NCT05014555
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
GI Alliance
Other
Eligibility
18 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Jacksonville, Florida • Baton Rouge, Louisiana • Southlake, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls

NCT01860963
View directory record Official record
Conditions
Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA
Interventions
Anal Pap smear and HPV DNA testing
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 85 Years
Enrollment
310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 3 Interventional

Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

NCT00338650
View directory record Official record
Conditions
Crohn's Disease
Interventions
adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 4 Interventional Results available

A Study of Infliximab for Treatment Resistant Major Depression

NCT00463580
View directory record Official record
Conditions
Depression
Interventions
Infliximab, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Sep 30, 2026, 7:23 PM EDT
Recruiting Phase 2 Interventional

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

NCT07657312
View directory record Official record
Conditions
Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography, Talquetamab, Teclistamab, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Naresh Bumma
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Not listed Phase 1Phase 2 Interventional

Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema

NCT00959725
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Infliximab (intravitreal, 2.0mg/0.05ml)
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2009 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 3 Interventional Results available

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

NCT00124982
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Anti-Tumor Necrosing Factor (TNF) Therapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
114
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration

NCT00304954
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Intravenous Daclizumab, Intravenous Infliximab, Observation, Oral Rapamycin
Drug · Other
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 92 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Sep 30, 2026, 7:23 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

NCT00808210
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Infliximab, Methotrexate, Methylprednisolone, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Sep 30, 2026, 7:23 PM EDT
Terminated Phase 3 Interventional Results available

A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)

NCT01962974
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Golimumab 2 mg/kg IV
Biological
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years to 76 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
47
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 30, 2026, 7:23 PM EDT
Completed No phase listed Observational

A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy

NCT04571697
View directory record Official record
Conditions
Dementia, Alzheimer Disease
Interventions
Methotrexate, Anti-TNF
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
34,647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Sep 30, 2026, 7:23 PM EDT
Completed No phase listed Observational

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

NCT03056924
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis

NCT00586599
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
measurement of inflammatory markers
Other
Lead sponsor
Indiana University
Other
Eligibility
7 Years to 17 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Sep 30, 2026, 7:23 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Diagnosis of Intestinal Motility by Image Analysis Using Capsule Endoscopy

NCT01085513
View directory record Official record
Conditions
Intestinal Abnormalities
Interventions
PillCam SB2
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
16 Years to 80 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)

NCT01844804
View directory record Official record
Conditions
Healthy
Interventions
PF-06438179, Remicade
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Sep 30, 2026, 7:23 PM EDT
Completed No phase listed Observational

Entyvio (Vedolizumab) Long Term Safety Study

NCT02674308
View directory record Official record
Conditions
Ulcerative Colitis and Crohn's Disease
Interventions
Vedolizumab, Other Biologic Agents
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
5,302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 30, 2026, 7:23 PM EDT